Confronto
Liraglutide vs. Retatrutide
Due peptidi a confronto — identità, base di evidenze, stato legale ed eventi avversi noti.
Identità
Categoria
Metabolico
Metabolico
N. CAS
204656-20-2
2381089-83-2
Peso molecolare
3751 g/mol
4731.6 g/mol
Emivita
13 h
144 h
Sequenza
HAEGTFTSDVSSYLEGQAAKEFIAWLVRGRGY-Aib-EGTFTSDYSIYLDKQAAQDFVQWLLDTGPSSGAPPPSMeccanismo d'azione
Liraglutide
Liraglutide is a synthetic GLP-1 analog with 97% sequence identity to human GLP-1. A fatty-acid side chain (C16) on Lys-26 reversibly binds serum albumin and protects against DPP-4 degradation. GLP-1 receptor activation glucose-dependently stimulates insulin secretion, inhibits glucagon secretion, delays gastric emptying and modulates central satiety.
Retatrutide
Retatrutide is a 39-amino-acid peptide with agonism at three incretin/energy-balance receptors: GLP-1R (insulin secretion, satiety), GIPR (insulin sensitivity, lipid metabolism) and the glucagon receptor (energy expenditure, lipolysis). The added glucagon activation is intended to raise catabolic energy expenditure while concurrent GLP-1/GIP action compensates the hyperglycaemic effect. Albumin binding via a fatty-acid side chain enables weekly dosing.
Base di evidenze
Evidenza più alta
RCT sull'uomo
RCT sull'uomo
Studi
5
5
di cui sull'uomo
4
4
Effetti registrati
3
4
Contraddizioni aperte
1
1
Eventi avversi documentati
1
2
Stato legale
Voci complete
Frequently asked questions
- What is the difference between Liraglutide and Retatrutide?
- Liraglutide is classified as "Metabolico", while Retatrutide is classified as "Metabolico". Liraglutide: GLP-1 receptor agonist with a half-life of about 13 hours. The first daily (not weekly) modern GLP-1 RA — approved as Victoza for type 2 diabetes (2010) and Saxenda for obesity (2014). Retatrutide: Synthetic triagonist peptide that simultaneously activates the GLP-1, GIP and glucagon receptors. Developed by Eli Lilly; in phase-3 trials for obesity (TRIUMPH programme) and type 2 diabetes. No marketing approval yet. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Liraglutide or Retatrutide?
- The highest available evidence level is "RCT sull'uomo" for Liraglutide and "RCT sull'uomo" for Retatrutide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Liraglutide and Retatrutide in Germany and the United States?
- Germania: Liraglutide — Su prescrizione, Retatrutide — Non approvato. Stati Uniti: Liraglutide — Su prescrizione, Retatrutide — Non approvato. These are factual summaries with source and review date on the individual pages.